Table of Contents
Overview
New York, NY – June 05, 2025 – Global Vaccines Market size is expected to be worth around US$ 136.4 billion by 2034 from US$ 79.1 billion in 2024, growing at a CAGR of 5.6% during the forecast period 2025 to 2034.
he global vaccine market is experiencing significant growth, driven by increasing immunization efforts, expanded disease prevention programs, and supportive global health initiatives. Vaccines play a critical role in reducing the burden of infectious diseases, especially in vulnerable populations such as children, the elderly, and immunocompromised individuals. According to the World Health Organization (WHO), immunization prevents 4 to 5 million deaths annually, underscoring its essential role in public health strategies.
Governments and international organizations are investing heavily in vaccine development and distribution. Programs such as Gavi, the Vaccine Alliance, and COVAX have enhanced access to life-saving vaccines in low- and middle-income countries. Technological advancements, including mRNA platforms and recombinant vector-based vaccines, have revolutionized the speed and efficacy of vaccine production.
The COVID-19 pandemic further highlighted the importance of scalable vaccine infrastructure and global cooperation. Ongoing R&D investments are now expanding to include vaccines for respiratory syncytial virus (RSV), tuberculosis, and universal influenza.
North America leads the market in terms of revenue due to strong healthcare infrastructure and supportive regulatory frameworks. However, the Asia-Pacific region is projected to grow rapidly, supported by rising awareness, improving healthcare access, and government immunization programs.
Key Takeaways
- In 2024, the global vaccines market generated revenue of approximately USD 79.1 billion. It is projected to grow at a compound annual growth rate (CAGR) of 5.6%, reaching USD 136.4 billion by 2033.
- Based on product type, the market is categorized into subunit vaccines, viral vector vaccines, mRNA vaccines, live attenuated vaccines, and inactivated vaccines. Among these, mRNA vaccines held the leading position in 2023, accounting for 38.4% of the total market share.
- In terms of route of administration, the market is segmented into oral, parenteral, and nasal routes. The parenteral segment emerged as the most significant, representing 52.6% of the total market.
- By application, the vaccine market is classified into viral diseases, bacterial vaccines, cancer vaccines, and allergy vaccines. Vaccines for viral diseases dominated the segment, contributing 44.2% of overall revenue.
- The distribution channel segment includes hospital and retail pharmacies, government suppliers, and others. Government suppliers led this category, holding a revenue share of 48.5%.
- Regionally, North America remained the dominant market in 2023, securing the largest revenue share of 42.1%, driven by advanced healthcare systems and widespread immunization programs.
Global Demand of Vaccines
Global demand for vaccines has been sustained by routine immunization programs and expanded adult vaccination initiatives. In 2023, the third dose coverage of diphtheria-tetanus-pertussis (DTP3) remained at 84 percent, indicating that 108 million infants received the antigen, while 14.5 million children did not receive any dose of DTP, representing an increase from 13.9 million in 2022. UNICEF procured more than 2 billion vaccine doses in 2023 to supply nearly half of the world’s children under five, reflecting an estimated annual procurement capacity equivalent to 45 percent of global requirements for pediatric immunization.
The COVID-19 pandemic spurred additional demand, with updated monovalent formulations distributed for all persons aged six months and older during 2024–2025 to counteract waning immunity against emerging SARS-CoV-2 variants. Meanwhile, the introduction of higher-valency pneumococcal conjugate vaccines (e.g., PCV15, PCV20) between 2021 and 2024 has increased demand for broader serotype coverage.
Demand forecasting is being refined through immunization coverage assessments that identified 2.7 million additional un- or under-vaccinated children in 2023 compared to pre-pandemic levels, underscoring persistent coverage gaps and the need for targeted catch-up and routine campaigns.
Segmentation Analysis
- Product Type Analysis: In 2023, mRNA vaccines accounted for 38.4% of the market share, driven by their success against COVID-19. The ability to produce these vaccines rapidly with high efficacy and adaptability has strengthened their role in combating various infectious diseases, including influenza and Zika. Continued innovation in mRNA platforms is expected to support broader vaccine development, positioning this segment as a leading contributor to future vaccine advancements and global immunization efforts.
- Route of Administration Analysis: Parenteral vaccines dominated with a 52.6% market share, largely due to the reliability of intramuscular and subcutaneous delivery methods. This route ensures strong immune responses and longer-lasting protection, making it the preferred choice for most immunization programs. The rising need for booster doses and pandemic readiness are expected to sustain this trend. Furthermore, innovations in needle-free technologies may further enhance acceptance and accessibility of injectable vaccines across healthcare systems globally.
- Application Analysis: The viral diseases segment led with a 44.2% revenue share, supported by rising cases of infections like influenza, hepatitis, and HPV. Intensified global immunization programs and advancements in vaccine R&D have propelled this segment’s growth. Increasing public awareness and efforts to develop universal vaccines against multiple viral strains are also boosting demand. The focus on preventing future pandemics is expected to further strengthen the market for viral disease vaccines in the coming years.
- Distribution Channel Analysis: Government suppliers represented 48.5% of total vaccine distribution revenue, as public-sector efforts remain central to global immunization initiatives. Their role in vaccine procurement and distribution ensures equitable access, particularly in low- and middle-income countries. Post-COVID funding boosts and expanded vaccination schedules are strengthening this segment. Additionally, international health partnerships and pandemic preparedness strategies are driving sustained investment, positioning government agencies as key players in future vaccine supply chains.
Market Segments
Product Type
- Subunit Vaccines
- Recombinant vaccines
- Conjugate Vaccines
- Toxoid vaccines
- Viral vector vaccines
- mRNA vaccines
- Live Attenuated
- Inactivated
Route of Administration
- Oral
- Parenteral
- Nasal
Application
- Viral Diseases
- Hepatitis
- Influenza
- Rotavirus
- Others
- Bacterial Vaccines
- Meningococcal Diseases
- Pneumococcal diseases
- DPT
- Others
- Cancer Vaccines
- Allergy Vaccines
Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
Regional Analysis
North America held the largest revenue share of 42.1% in the global vaccine market in 2023, driven by increasing demand for immunization programs and technological advancements. The approval of PCV15 (Vaxneuvance) by the U.S. FDA in June 2022 for pediatric pneumococcal disease prevention reinforced the region’s emphasis on childhood immunization. Rising awareness of preventive healthcare, coupled with a higher prevalence of infectious diseases, supported wider vaccine adoption across age groups. Government-led funding and seasonal immunization initiatives further contributed to growth.
Additionally, rapid innovation in mRNA platforms and next-generation formulations enhanced production and efficacy, while collaborations between pharmaceutical and biotech firms streamlined development and distribution.
Asia Pacific is projected to register the highest CAGR during the forecast period due to expanding immunization programs and healthcare infrastructure. Countries such as China, India, and Japan are investing in large-scale vaccination campaigns, supported by favorable regulatory frameworks and international partnerships.
Maxvax Biotechnology’s USD 82.5 million Series C funding in July 2024 highlights regional momentum. AI-based research and modern manufacturing methods are also driving innovation. Efforts to reduce vaccine hesitancy and improve outreach through public-private collaboration are expected to significantly boost vaccine uptake in the region.
Emerging Trends
A significant advancement has been observed in messenger RNA (mRNA) vaccine platforms. The rapid development and rollout of mRNA-based vaccines during the COVID-19 pandemic have facilitated their exploration for other infections such as influenza and respiratory syncytial virus (RSV). Innovations in antigen design, including optimized mRNA constructs and novel lipid nanoparticle formulations, are being pursued to enhance immune responses and broaden protection against emerging variants. Additionally, candidate mRNA vaccines for pathogens such as human immunodeficiency virus (HIV), malaria, and tuberculosis are being tracked by the World Health Organization’s vaccine pipeline, with periodic updates every six months.
Efforts to increase vaccine valency and combine multiple antigens into single formulations have gained momentum. For pneumococcal disease, higher-valency conjugate vaccines (PCV15, PCV20, and PCV21) have been introduced between 2021 and 2024 to cover additional serotypes that cause invasive disease. Likewise, influenza vaccine composition is being regularly updated to match circulating strains; for the 2025–2026 northern hemisphere season, WHO recommended specific hemagglutinin antigens to optimize effectiveness against evolving influenza viruses. Such polyvalent and tailored vaccine approaches are aimed at improving coverage and reducing the burden of vaccine-preventable illnesses.
An increased emphasis on adult immunization has been noted, with vaccines previously targeted primarily at children now being extended to older age groups. RSV immunization rates among adults aged 60–74 years with high-risk conditions were reported at approximately 38.1% as of April 26, 2025, reflecting growing uptake of novel RSV vaccines. Concurrently, COVID-19 vaccines are being recommended for all persons aged ≥6 months, and additional doses are advised to counteract waning immunity against emergent SARS-CoV-2 variants (e.g., Omicron JN.1 and KP.2 lineages). This shift toward adult and booster immunization is expected to mitigate severe disease and hospitalization across all age cohorts.
Attention to global immunization equity and surveillance has intensified as coverage gaps threaten to reverse progress. In 2025, infant vaccination coverage was reported to be declining in regions such as Kenya, exposing populations to outbreaks of measles, polio, and other preventable diseases. Simultaneously, meningitis cases in Africa surged to over 5,500 suspected cases with nearly 300 deaths in the first quarter of 2025, underscoring the need for strengthened vaccination campaigns and outbreak response. To address these challenges, investments in routine immunization systems, community engagement, and targeted catch-up campaigns are being prioritized by global health authorities.
Use Cases
COVID-19 vaccines have been broadly deployed across age groups to reduce morbidity and mortality. For the 2024–2025 season, monovalent XBB.1-strain vaccines (Moderna, Pfizer-BioNTech, and Novavax) were recommended for individuals aged ≥6 months. Interim estimates showed that vaccination with the 2024–2025 COVID-19 formula reduced the risk of influenza-like illness and hospitalization in children and adults. Additional doses were authorized under FDA Emergency Use Authorization for those aged 6 months–11 years (Moderna, Pfizer-BioNTech) and ≥12 years (Novavax), further supporting immune protection against evolving SARS-CoV-2 variants.
Seasonal influenza vaccines continue to play a critical public health role by lowering outpatient visits and hospital admissions. During the 2024–2025 influenza season, manufacturers projected supply of up to 148 million doses in the United States. Interim effectiveness estimates indicated that vaccination reduced outpatient visits and hospitalizations among all age groups, supporting CDC and ACIP recommendations for annual vaccination of persons aged ≥6 months. Such quantifiable impact underscores the importance of widespread flu immunization in controlling seasonal epidemics.
Human papillomavirus (HPV) vaccines have been introduced or optimized in several countries to prevent cervical cancer and other HPV-related diseases. In 2024, four new countries adopted HPV vaccination programs, and 25 countries transitioned to the WHO-recommended single-dose schedule, simplifying logistics and improving uptake. This expansion is anticipated to reduce HPV infection rates and related malignancies, particularly in low- and middle-income settings where cervical cancer remains a leading cause of cancer-related death among women.
Respiratory syncytial virus (RSV) vaccines have been recommended for older adults and certain high-risk groups to prevent severe respiratory illness. As of April 2025, 38.1% of adults aged 60–74 years with risk factors reported having received an RSV vaccine. Immunization in this cohort is projected to substantially decrease hospitalizations and healthcare utilization during peak RSV circulation. In parallel, surveillance of viral vaccine-preventable diseases informs decisions on RSV vaccine policy and supports targeted immunization strategies in long-term care facilities and community settings.
Conclusion
The global vaccine market is poised for sustained growth, supported by advances in mRNA technology, increasing adult immunization, and strong public health initiatives. Expanding disease prevention efforts, especially in low- and middle-income countries, continue to drive demand for vaccines against viral, bacterial, and emerging infections.
Rising investments, regulatory support, and global collaborations are enhancing innovation and equitable access. While North America leads in revenue, Asia-Pacific is emerging as a high-growth region. As immunization programs evolve to address shifting epidemiological patterns, the vaccine market will remain central to reducing disease burden and improving public health outcomes across diverse populations.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
